

doi: 10.13241/j.cnki.pmb.2020.12.033

丙泊酚联合瑞芬太尼麻醉对直肠癌根治术患者血流动力学和 T 淋巴细胞亚群的影响 *

何晓华¹ 李晓滨^{2△} 杨宜科³ 吴绪才⁴ 肖莉⁴

(1 广西医科大学第八附属医院麻醉科 广西 贵港 537120; 2 宝鸡市中医医院麻醉科 陕西 宝鸡 721000;

3 广西中医药大学第一附属医院麻醉科 广西 南宁 530023; 4 西安交通大学医学院附属红会医院麻醉科 陕西 西安 710054)

摘要 目的:探讨直肠癌根治术患者采用丙泊酚联合瑞芬太尼麻醉维持的临床效果。**方法:**选取 2016 年 3 月~2019 年 3 月期间在我院行直肠癌根治术的患者 82 例,根据乱数表法将患者分为对照组($n=41$)和研究组($n=41$),其中对照组给予七氟醚麻醉维持,研究组给予丙泊酚联合瑞芬太尼麻醉维持,比较两组患者围术期指标、血流动力学和 T 淋巴细胞亚群变化,记录两组围术期不良反应情况。**结果:**研究组患者的清醒时间、拔管时间均短于对照组($P<0.05$)。两组患者麻醉成功后(T_2)~术后 72 h(T_5)时间点心率(HR)、平均动脉压(MAP)均呈先降低后升高趋势($P<0.05$);研究组 T_2 ~术后 24 h(T_4)时间点 HR、MAP 高于对照组($P<0.05$)。两组不良反应发生率对比无差异($P>0.05$)。两组患者 T_2 ~ T_5 时间点 $CD4^+$ 、 $CD4^+/CD8^+$ 均呈先降低后升高趋势($P<0.05$), $CD8^+$ 呈先升高后降低趋势($P<0.05$);研究组 T_2 ~ T_4 时间点 $CD4^+$ 、 $CD4^+/CD8^+$ 高于对照组($P<0.05$), $CD8^+$ 低于对照组($P<0.05$)。**结论:**直肠癌根治术患者麻醉维持选用丙泊酚联合瑞芬太尼可减少对机体血流动力学的影响,减轻免疫抑制,改善围术期相关指标,且不增加不良反应发生率。

关键词:丙泊酚;瑞芬太尼;直肠癌根治术;血流动力学;T 淋巴细胞亚群

中图分类号:R735.37;R614 **文献标识码:**A **文章编号:**1673-6273(2020)12-2351-04

Effects of Propofol Combined with Remifentanyl Anesthesia on Hemodynamics and T Lymphocyte Subsets in Patients Undergoing Radical Resection of Rectal Cancer*

HE Xiao-hua¹, LI Xiao-bin^{2△}, YANG Yi-ke³, WU Xu-cai⁴, XIAO Li⁴

(1 Department of Anesthesiology, Eighth Affiliated Hospital of Guangxi Medical University, Guigang, Guangxi, 537120, China;

2 Department of Anesthesiology, Baoji Traditional Chinese Medicine Hospital, Baoji, Shaanxi, 721000, China;

3 Department of Anesthesiology, The First Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning, Guangxi, 530023, China; 4 First Department of Anesthesiology, Honghui Hospital Affiliated to Medical College of Xi'an Jiaotong University,

Xi'an, Shaanxi, 710054, China)

ABSTRACT Objective: To investigate the effects of propofol combined with remifentanyl anesthesia on hemodynamics and T lymphocyte subsets in patients undergoing radical resection of rectal cancer. **Methods:** 82 patients with rectal cancer who underwent radical operation in our hospital from March 2016 to March 2019 were selected, and they were divided into control group ($n=41$) and study group ($n=41$) according to random number table method. The control group was given sevoflurane anesthesia for maintenance, and the study group was given propofol combined with remifentanyl anesthesia maintenance. Perioperative indexes, hemodynamics and T lymphocyte subsets were compared between the two groups, and adverse reactions during treatment were recorded between the two groups. **Results:** The awakening time and extubation time of the study group were shorter than those of the control group ($P<0.05$). Heart rate (HR) and central venous pressure (MAP) decreased first and then increased after successful anesthesia (T_2)~72 h after anesthesia (T_5) between the two groups ($P<0.05$). HR and MAP in the study group at T_2 ~24 h after anesthesia (T_4) were higher than those in the control group ($P<0.05$). There was no significant difference in the incidence of adverse reactions between the two groups ($P>0.05$). The $CD4^+$, $CD4^+/CD8^+$ in both groups decreased at first and then increased at T_2 ~ T_5 time points ($P<0.05$). $CD8^+$ increased first and then decreased ($P<0.05$). $CD4^+$, $CD4^+/CD8^+$ in the study group at T_2 ~ T_4 time points were higher than those in the control group ($P<0.05$), and $CD8^+$ was lower than that in the control group ($P<0.05$). **Conclusion:** Propofol combined with remifentanyl anesthesia can reduce the hemodynamic effects, alleviate immune suppression, improve perioperative related indicators, and do not increase the incidence of adverse reactions in patients undergoing radical resection of rectal cancer.

* 基金项目:广西科技攻关计划基金项目(1512400417)

作者简介:何晓华(1982-),女,硕士,主治医师,研究方向:临床麻醉,E-mail:gxhexiaohua@163.com

△ 通讯作者:李晓滨(1980-),男,本科,主治医师,研究方向:麻醉与疼痛,E-mail:157876000@qq.com

(收稿日期:2019-10-24 接受日期:2019-11-20)

Key words: Propofol; Remifentanyl; Radical resection of rectal cancer; Hemodynamics; T lymphocyte subsets

Chinese Library Classification(CLC): R735.37; R614 **Document code:** A

Article ID: 1673-6273(2020)12-2351-04

前言

直肠癌是指从齿状线至直肠乙状结肠交界处之间的癌,是消化系统常见的恶性肿瘤之一^[1]。现临床针对直肠癌的治疗主要以手术治疗为主,直肠癌根治术可有效阻止患者疾病进展,其手术的安全性及根治性也逐渐得到认可^[2]。但直肠癌根治术作为有创手术,术中及麻醉刺激均可引起机体不同程度的血流动力学变化和免疫功能下降,影响患者术后恢复^[3,4]。此外,由于直肠癌的多发群体为40~60岁的中老年人,此类患者身体各项技能逐渐下降,对手术和麻醉耐受性差,若处理不当,可诱发各种并发症,加重机体功能障碍^[5]。不少临床实践证实^[6,7],围术期中合理的麻醉方案可保证手术的顺利进行,故寻找安全、有效的麻醉方法对改善直肠癌根治术患者预后具有积极的临床意义。丙泊酚为新型的短效麻醉药,常用于全身麻醉诱导和麻醉维持中,发挥较好的镇静、镇痛作用^[8]。瑞芬太尼为阿片类新型药物,具有麻醉起效快、半衰期短等优点^[9]。本研究对在我院行直肠癌根治术的患者术中给予丙泊酚联合瑞芬太尼麻醉维持,效果较好,报道如下。

1 资料与方法

1.1 基线资料

选取2016年3月~2019年3月于我院行直肠癌根治术的82例患者。纳入标准:(1)均符合《直肠癌规范化诊疗指南(试行)》^[10]中直肠癌的诊断标准,并经病理实验等证实;(2)均在我院择期行直肠癌根治术者;(3)美国麻醉医师协会(American Society of Anesthesiologists, ASA)分级Ⅰ~Ⅱ级者;(4)患者及其家属知情本研究且签署同意书;(5)均符合手术指征者。排除标准:(1)对本次研究用药存在禁忌症者;(2)合并其他肿瘤疾病者;(3)合并凝血功能障碍者;(4)合并心肝肾等重要脏器功能不全者;(5)合并免疫缺陷者。此次研究已获取我院伦理学委员会批准同意。根据乱数表法将患者分为对照组(n=41)和研究组(n=41),其中对照组男26例,女15例,年龄38~62岁,平均(49.82±3.46)岁;ASA分级:Ⅰ级24例,Ⅱ级17例;病理类型:浸润型13例,隆起型14例,溃疡型14例;分化程度:低分化15例,中分化17例,高分化9例。研究组男24例,女17例,年龄36~61岁,平均(50.09±3.62)岁;ASA分级:Ⅰ级23例,Ⅱ级18例;病理类型:浸润型13例,溃疡型12例,隆起型16

例;分化程度:低分化14例,中分化16例,高分化11例。两组一般资料比较无差异($P>0.05$)。

1.2 方法

所有患者入院后行常规检查,择期行直肠癌根治术。所有患者麻醉前30 min肌注阿托品0.5 mg,咪唑安定3 mg,入室后常规监测心率(Heart rate, HR)、平均动脉压(MAP),建立静脉通路,实施面罩吸氧。两组患者均给予以下药物行麻醉诱导:舒芬太尼(国药准字H20054256,宜昌人福药业有限责任公司,规格:按舒芬太尼计5 mL:250 μg/0.4 μg/kg,咪达唑仑注射液(国药准字H20153019,江苏九旭药业有限公司,规格:3 mL:15 mg)0.1 mg/kg,顺苯磺酸阿曲库铵(国药准字H20090202,浙江仙琚制药股份有限公司,规格:5 mg(以顺阿曲库铵计)0.5 mg/kg,丙泊酚注射液(国药准字H20123318,西安力邦制药有限公司,规格:50 mL:1.0 g)4~6 mg/h,静脉注射。诱导成功后,行气管插管。对照组麻醉维持选用1~3%七氟醚静脉输注直至术毕;研究组麻醉维持:丙泊酚注射液0.5 μg/kg·min,瑞芬太尼(国药准字H20143315,江苏恩华药业股份有限公司,规格:2 mg(以瑞芬太尼计))0.1~0.25 μg/kg·min,静脉输注直至术毕。术后给予常规抗感染、镇痛处理。

1.3 观察指标

(1)记录两组患者清醒时间和拔管时间,其中清醒时间为手术结束至唤醒,拔管时间为手术结束至拔管。(2)记录两组患者麻醉前(T_1)、麻醉成功后(T_2)、术毕即刻(T_3)、术后24h(T_4)、术后72h(T_5)等时间点的血流动力学指标:HR、MAP。(3)于 T_1 ~ T_5 抽取患者肘静脉血2 mL,经4600 r/min离心15 min,离心半径8 cm,取上清置于-30℃冰箱中待测。采用流式细胞仪(美国Coulter公司EPICS-XL型)检测T淋巴细胞亚群:CD4⁺、CD8⁺,计算CD4⁺/CD8⁺。(4)记录两组围术期不良反应。

1.4 统计学方法

数据分析采用SPSS25.0进行,以率表示计数资料,行 χ^2 检验,计量资料以($\bar{x} \pm s$)的形式表示,行t检验。检验标准设置为 $\alpha=0.05$ 。

2 结果

2.1 两组围术期指标比较

研究组患者的清醒时间、拔管时间均短于对照组($P<0.05$)。详见表1。

表1 两组围术期指标比较($\bar{x} \pm s$, min)

Table 1 Comparison of perioperative indicators between two groups($\bar{x} \pm s$, min)

Groups	Awakening time	Extubation time
Control group(n=41)	11.95±1.26	18.48±1.78
Study group(n=41)	8.16±1.21	13.27±1.69
t	13.892	13.592
P	0.000	0.000

2.2 两组血流动力学指标比较

升高趋势($P<0.05$); 研究组 $T_2\sim T_4$ 时间点 HR、MAP 高于对照组两组患者 T_1 时间点 HR、MAP 比较无差异($P>0.05$); 与 T_1 ($P<0.05$); 详见表 2。时间点比较, 两组患者 $T_2\sim T_5$ 时间点 HR、MAP 均呈先降低后表 2 两组血流动力学指标比较($\bar{x}\pm s$)Table 2 Comparison of hemodynamic parameters between two groups($\bar{x}\pm s$)

Groups	Time points	HR(Times/min)	MAP(mmHg)
Control group(n=41)	T_1	80.26±5.13	103.39±8.23
	T_2	64.35±6.02 ^a	85.11±7.18 ^a
	T_3	68.24±7.42 ^{ab}	90.26±7.78 ^{ab}
	T_4	73.19±6.33 ^{abc}	94.84±7.65 ^{abc}
	T_5	79.14±6.54 ^{bcd}	101.18±9.95 ^{bcd}
Study group(n=41)	T_1	80.28±7.23	104.35±7.73
	T_2	68.36±6.26 ^{ac}	89.52±8.42 ^{ac}
	T_3	72.67±6.87 ^{abc}	94.83±7.31 ^{abc}
	T_4	76.81±6.15 ^{abce}	98.53±8.54 ^{abce}
	T_5	79.93±6.3 ^{bcd}	102.13±8.27 ^{bcd}

Note: Compared with T_1 time point, ^a $P<0.05$; compared with T_2 time point, ^b $P<0.05$; compared with T_3 time point, ^c $P<0.05$; compared with T_4 time point, ^d $P<0.05$; compared with control group, ^e $P<0.05$.

2.3 两组 T 淋巴细胞亚群比较

低后升高趋势 ($P<0.05$), $CD8^+$ 呈先升高后降低趋势($P<0.05$);

两组患者 T_1 时间点 $CD4^+$ 、 $CD8^+$ 、 $CD4^+/CD8^+$ 比较无差异 研究组 $T_2\sim T_4$ 时间点 $CD4^+$ 、 $CD4^+/CD8^+$ 高于对照组 ($P<0.05$), ($P>0.05$); 两组患者 $T_2\sim T_5$ 时间点 $CD4^+$ 、 $CD4^+/CD8^+$ 均呈先降 $CD8^+$ 低于对照组 ($P<0.05$); 详见表 3。

表 3 两组 T 淋巴细胞亚群比较($\bar{x}\pm s$)Table 3 Comparison of T lymphocyte subsets between two groups($\bar{x}\pm s$)

Groups	Time points	$CD4^+$	$CD8^+$	$CD4^+/CD8^+$
Control group(n=41)	T_1	57.18±6.14	24.84±3.99	2.30±0.29
	T_2	48.91±6.05 ^a	31.93±4.01 ^a	1.53±0.31 ^a
	T_3	45.09±6.27 ^{ab}	35.28±2.26 ^{ab}	1.28±0.26 ^{ab}
	T_4	49.13±6.41 ^{ac}	30.28±2.37 ^{ac}	1.62±0.32 ^{ac}
	T_5	55.42±5.58 ^{bcd}	24.93±2.74 ^{bcd}	2.22±0.26 ^{bcd}
Study group(n=41)	T_1	57.22±6.47	24.97±3.82	2.29±0.27
	T_2	53.29±5.71 ^{ac}	27.84±3.12 ^{ac}	1.91±0.19 ^{ac}
	T_3	48.17±6.62 ^{abc}	31.85±3.16 ^{abc}	1.51±0.22 ^{abc}
	T_4	52.41±5.87 ^{acc}	28.20±3.83 ^{acc}	1.86±0.19 ^{acc}
	T_5	56.96±6.02 ^{bcd}	25.18±2.90 ^{bcd}	2.26±0.21 ^{bcd}

Note: Compared with T_1 time point, ^a $P<0.05$; compared with T_2 time point, ^b $P<0.05$; compared with T_3 time point, ^c $P<0.05$; compared with T_4 time point, ^d $P<0.05$; compared with control group, ^e $P<0.05$.

2.4 不良反应比较

对照组围术期出现躁动、寒战、恶心呕吐、低血压各 1 例, 心动过缓 2 例, 不良反应发生率为 14.63%(6/41), 研究组围术期出现心动过缓、躁动、低血压各 2 例, 寒战、恶心呕吐各 1 例, 不良反应发生率为 19.51%(8/41), 经比较两组不良反应发生率无差异($\chi^2=0.345$, $P=0.557$)。

3 讨论

直肠癌发病率较高, 在我国其发病率仅次于胃癌^[11]。近年来随着人们生活水平的改善, 饮食结构不断发生变化, 致使直肠癌的发病率呈逐年递增趋势, 已成为危害人类生命健康的主要疾病之一^[12]。直肠癌根治术是治疗直肠癌的主要方式, 该术式手术成功率高、术后恢复快, 可有效阻止直肠癌病情进展^[13]。但该术式作为有创术式, 由于手术创伤、术中刺激以及术后疼痛可使机体产生强烈的应激反应, 造成机体血流波动, 导致患者免疫功能降低, 术后感染发生风险增加^[14,15], 其具体的手术效

果很大程度上受麻醉方法的影响,故寻找一种科学、安全的麻醉方法尤为必要。丙泊酚静脉注射后可保护机体各组织器官、调节免疫、镇静、抑制血小板聚集、止痛,且具有苏醒时间短、控制性强、危害小等优势,然而单一的镇痛存在较多不足,剂量过少难以达到镇痛效果,剂量过多又易增加呼吸抑制等不良反应发生风险^[16,17]。现临床多主张多模式镇痛以达到最佳的麻醉效果。瑞芬太尼为阿片类新型药物,静脉滴注后可迅速达到有效药物浓度,发挥镇静、镇痛的效果^[18,19]。

本次研究结果显示,两组患者不同时间点 HR、MAP 均呈先降低后升高趋势,研究组不同时间点 HR、MAP 高于对照组,可见两种麻醉方式均可引起患者的血流波动,但丙泊酚联合瑞芬太尼麻醉者的血流波动可明显减轻,分析其原因,丙泊酚进入机体后,主要作用于 γ -氨基丁酸受体复合物,产生较好的麻醉效果^[20],而瑞芬太尼衍生于芬太尼,相较于芬太尼,瑞芬太尼效用较强,可有效抑制机体应激反应,减轻手术对患者呼吸、循环系统、压力感受器功能的影响,对 HR 影响较轻,同时瑞芬太尼还可作用于冠状血管,促进其扩张,改善 MAP^[21,22]。因此,瑞芬太尼联合丙泊酚使用可在药代动力学方面发挥协同效果,增强药效,提高麻醉效果,起到稳定 HR、MAP 的作用。细胞免疫在机体抗肿瘤免疫效应中作用显著,T 淋巴细胞亚群为关键性免疫活性细胞,其中 CD8⁺ 可抑制 T 细胞增生和抗体分泌,CD4⁺ 主要表达于抑制细胞核杀伤性 T 细胞表面,可辅助 B 细胞分化产生抗体^[23,24]。而 CD4⁺/CD8⁺ 的比值降低则预示着机体免疫功能的下降。本次研究结果中,两组患者围术期间免疫功能均有不同程度的下降,但研究组免疫功能下降的程度更轻,表明丙泊酚联合瑞芬太尼麻醉可有效缓解免疫抑制。丙泊酚静脉注射后本身就具有调节免疫的作用,且瑞芬太尼可削弱 μ 受体对 T 淋巴细胞的抑制,同时还可通过刺激 K 受体,抑制神经递质,减轻机体创伤刺激,保护机体免疫功能^[25-27]。此外研究组患者的清醒时间、拔管时间均短于对照组,这可能是因为瑞芬太尼对机体呼吸的抑制较为缓和,患者术后可尽早恢复,同时联合丙泊酚用药,具有可控性高、反复给药无蓄积等优势^[28]。两组不良反应发生率对比未见显著差异,可见本次联合麻醉用药安全性较好,不会增加不良反应发生率,这可能是因为瑞芬太尼的代谢几乎不受患者肝肾功能影响,药物残留少^[29],而丙泊酚则具有保护机体各组织器官的药效作用,安全性较好^[30]。

综上所述,直肠癌根治术患者选用丙泊酚联合瑞芬太尼麻醉维持,可减轻免疫抑制,减少对机体血流动力学的影响,改善围术期指标,临床应用价值较高。

参考文献(References)

- [1] Cai D, Huang ZH, Yu HC, et al. Prognostic value of preoperative carcinoembryonic antigen/tumor size in rectal cancer [J]. *World J Gastroenterol*, 2019, 25(33): 4945-4958
- [2] Hwang Y, Yoon YS, Bong JW, et al. Long-term Transanal Excision Outcomes in Patients With T1 Rectal Cancer: Comparative Analysis of Radical Resection[J]. *Ann Coloproctol*, 2019, 35(4): 194-201
- [3] Kuo YH, Lai CH, Huang CY, et al. Monthly tegafur-uracil maintenance for increasing relapse-free survival in ypStage III rectal cancer patients after preoperative radiotherapy, radical resection, and 12 postoperative chemotherapy cycles: a retrospective study[J]. *BMC Cancer*, 2019, 19(1): 815
- [4] 胡振飞, 范涛, 李艳红, 等. 结直肠癌根治术患者丙泊酚静脉麻醉期血液流变学及血流动力学变化及意义 [J]. *现代生物医学进展*, 2017, 17(15): 2913-2916
- [5] Spinelli A, Montroni I. Personalized treatments for elderly patients affected by rectal cancer[J]. *Colorectal Dis*, 2017, 19(10): 879-880
- [6] Thiels CA, Bergquist JR, Meyers AJ, et al. Outcomes with multimodal therapy for elderly patients with rectal cancer[J]. *Br J Surg*, 2016, 103(2): e106-e114
- [7] Dubowitz JA, Sloan EK, Riedel BJ. Implicating anaesthesia and the perioperative period in cancer recurrence and metastasis [J]. *Clin Exp Metastasis*, 2018, 35(4): 347-358
- [8] 杨永斌, 杨秀梅. 芬太尼复合丙泊酚麻醉在小儿支气管异物取出术中的应用效果[J]. *陕西医学杂志*, 2019, 48(7): 882-884, 889
- [9] Anderson B. The Use of Remifentanyl as the Primary Agent for Analgesia in Parturients [J]. *Crit Care Nurs Clin North Am*, 2017, 29(4): 495-517
- [10] 中华人民共和国国家卫生和计划生育委员会. 直肠癌规范化诊疗指南(试行)[J]. *中国医学前沿杂志(电子版)*, 2013, 5(7): 56-61
- [11] 杜振双, 钟铁刚, 林建泉, 等. 低位直肠癌保肛术排便功能障碍的研究[J]. *中国现代普通外科进展*, 2017, 20(12): 1000-1002
- [12] Deng Y. Rectal Cancer in Asian vs. Western Countries: Why the Variation in Incidence?[J]. *Curr Treat Options Oncol*, 2017, 18(10): 64
- [13] Wright ME, Beaty JS, Thorson AG, et al. Cost-Effectiveness Analysis of Total Neoadjuvant Therapy Followed by Radical Resection Versus Conventional Therapy for Locally Advanced Rectal Cancer [J]. *Dis Colon Rectum*, 2019, 62(5): 568-578
- [14] 米超. 腹腔镜直肠癌根治术治疗直肠癌的疗效及对应激反应与预后的影响[J]. *空军医学杂志*, 2019, 35(4): 324-327
- [15] Du M, Liu B, Li M, et al. Multicenter surveillance study of surgical site infection and its risk factors in radical resection of colon or rectal carcinoma[J]. *BMC Infect Dis*, 2019, 19(1): 411
- [16] Chu C, Yi X, Sun J, et al. Comparison of anesthetic effects of dexmedetomidine and tramadol, respectively, combined with propofol in percutaneous microwave coagulation therapy for hepatocellular carcinoma[J]. *Oncol Lett*, 2019, 18(4): 3599-3604
- [17] 徐珊, 陈晓丽. 老年全膝关节置换术后不同镇痛方案效果阿片类药物使用量及首次康复训练时间比较[J]. *中国药物与临床*, 2019, 19(4): 613-616
- [18] Zhang J, Wang Y, Yang G, et al. Effects of comprehensive rehabilitation training in combination with multi-mode analgesia on body function recovery after tumor-type knee replacement [J]. *Pak J Med Sci*, 2016, 32(5): 1240-1245
- [19] 张康泰, 梁斌, 赵蕊, 等. 舒芬太尼、瑞芬太尼在急诊脑外伤手术麻醉中的临床应用[J]. *现代生物医学进展*, 2016, 16(33): 6570-6572, 6563
- [20] Brohan J, Goudra BG. The Role of GABA Receptor Agonists in Anesthesia and Sedation[J]. *CNS Drugs*, 2017, 31(10): 845-856
- [21] Lin W, Sun J, Fu S. A small dose of remifentanyl pretreatment suppresses sufentanil-induced cough during general anesthesia induction: a randomized, double-blind, placebo-controlled trial [J]. *BMC Anesthesiol*, 2019, 19(1): 164

- [18] Tang XS, Tan MS, Yi P, et al. Analysis of clinical outcome of kyphoplasty on costal pain related to thoracic osteoporotic compression fractures [J]. China Journal of Orthopaedics & Traumatology, 2017, 30(9): 823
- [19] Zhu G Y. Nomogram for Predicting Intradiscal Cement Leakage Following Percutaneous Vertebroplasty in Patients with Osteoporotic Related Vertebral Compression Fractures[J]. pain physician, 2017, 20 (4): E513
- [20] Zhang Y, Liu H, He F, et al. Safety and efficacy of percutaneous kyphoplasty assisted with O-arm navigation for the treatment of osteoporotic vertebral compression fractures at T6 to T9 vertebrae[J]. Int Orthop, 2020, 44(2): 349-355
- [21] Guenoun D, Fouré A, Pithioux M, et al. Correlative Analysis of Vertebral Trabecular Bone Microarchitecture and Mechanical Properties: A Combined Ultra-high Field (7 Tesla) MRI and Biomechanical Investigation[J]. Spine, 2017, 42(20): E1165
- [22] Takahashi S, Hoshino M, Terai H, et al. Differences in short-term clinical and radiological outcomes depending on timing of balloon kyphoplasty for painful osteoporotic vertebral fracture [J]. journal of orthopaedic science, 2018, 23(1): 51-56
- [23] R.J. McDonald, J.I. Lane, F.E. Diehn, et al. Percutaneous vertebroplasty: Overview, clinical applications, and current state[J]. Applied Radiology, 2017, 46(1): 24-30
- [24] Yi-Long Zhang, Li-Tao Shi, Pei-Fu Tang, et al. Correlation analysis of osteoporotic vertebral compression fractures and spinal sagittal imbalance[J]. Der Orthopäde, 2017, 46(3): 249
- [25] Huilin Yang, Liang Chen, Zhaomin Zheng, et al. Therapeutic effects analysis of percutaneous kyphoplasty for osteoporotic vertebral compression fractures: A multicentre study[J]. Journal of Orthopaedic Translation, 2017, 11(C): 73-77
- [26] Lei Duan, Guang-Chuan Yang, Wei-Zhong Tang, et al. Observation of clinical effects of percutaneous vertebroplasty in the treatment of vertebral compression fractures complicated with intravertebral clefts [J]. China Journal of Orthopaedics & Traumatology, 2018, 31 (4): 328-332
- [27] E Jonsson, O Ström, A Spångéus, et al. Risk of Major Osteoporotic Fracture (Hip, Vertebral, Radius, Humerus [MOF]) After First, Second and Third Fragility Fracture In A Swedish General Population Cohort[J]. Value in Health, 2017, 20(9): A528
- [28] Arima K, Abe Y, Nishimura T, et al. Association of vertebral compression fractures with physical performance measures among community-dwelling Japanese women aged 40 years and older [J]. BMC Musculoskeletal Disorders, 2017, 18(4): 881
- [29] Ivo K. Genev, Matthew K. Tobin, Saher P. Zaidi, et al. Spinal Compression Fracture Management[J]. Global Spine Journal, 2017, 7 (1): 71-82
- [30] H. Wei, X. Ma. Application of unilateral multiple channels approach in percutaneous vertebroplasty for osteoporotic vertebral fractures[J]. Cellular & Molecular Biology, 2017, 63(10): 69
- [31] Ali Genç, serdar özgen, suheyla uyar bozkurt, et al. Vertebral fracture due to a solitary bone cyst[J]. Journal of neurosurgical sciences, 2017, 61(2): 228-232
- [32] Shende Mulchand, Mendhekar Seema. Formulation of polyherbomineral matrices for treatment of osteoporosis [J]. Asian Journal of Pharmaceutical & Clinical Research, 2018, 11(1): 217-223
- [33] Stanghelle B, Bentzen H, Giangregorio L, et al. Effect of a resistance and balance exercise programme for women with osteoporosis and vertebral fracture: study protocol for a randomized controlled trial[J]. BMC Musculoskeletal Disorders, 2018, 19(1): 100
- [34] Hongyang Zhang, Xiaojuan Shi, Long Wang, et al. Intramembranous ossification and endochondral ossification are impaired differently between glucocorticoid-induced osteoporosis and estrogen deficiency-induced osteoporosis[J]. entific Reports, 2018, 8(1): 3867
- [35] Kristie N Tu, Janette D Lie, Chew King Victoria Wan, et al. Osteoporosis: A Review of Treatment Options [J]. P & T, 2018, 43(2): 92-104

(上接第 2354 页)

- [22] 张玉龙, 左友波, 杨宇焦. 瑞芬太尼联合舒芬太尼全麻对高龄腹部创伤手术患者应激反应、免疫功能及血流动力学的影响[J]. 成都医学院学报, 2019, 14(4): 467-470, 474
- [23] Sackstein R, Schatton T, Barthel SR. T-lymphocyte homing: an underappreciated yet critical hurdle for successful cancer immunotherapy[J]. Lab Invest, 2017, 97(6): 669-697
- [24] Barinov A, Galgano A, Krenn G, et al. CD4/CD8/Dendritic cell complexes in the spleen: CD8⁺ T cells can directly bind CD4⁺ T cells and modulate their response[J]. PLoS One, 2017, 12(7): e0180644
- [25] Li R, Liu H, Dilger JP, et al. Effect of Propofol on breast Cancer cell, the immune system, and patient outcome[J]. BMC Anesthesiol, 2018, 18(1): 77
- [26] 刘薇, 周李萍, 彭健. 瑞芬太尼复合麻醉对开腹结肠癌患者细胞因子、T 淋巴细胞亚群及氧化应激的影响 [J]. 海南医学, 2019, 30(8): 994-999
- [27] 毛延坤, 杭博, 曾渊. 瑞芬太尼联合丙泊酚静脉靶控麻醉对脑外科手术患者炎症反应、氧化应激及神经递质的影响[J]. 海南医学院学报, 2018, 24(23): 2050-2053
- [28] Sbaraglia F, Sammartino M. Propofol-remifentanyl and spontaneous breathing, a magnificent pair [J]. Minerva Anesthesiol, 2016, 82(11): 1129-1131
- [29] 王欣, 孙媛, 魏砚砚, 等. 不同靶控输注瑞芬太尼复合丙泊酚、右美托咪定用于精神分裂症剖宫产手术的影响[J]. 中国地方病防治杂志, 2017, 32(8): 900-901, 908
- [30] Li Volti G, Avola R, Tibullo D. Editorial-Propofol as an intraoperative strategy for organ protection [J]. Eur Rev Med Pharmacol Sci, 2017, 21(17): 3980-3981